Benefits for clinicians
With similar and overlapping symptoms, it’s impossible to know what’s causing a bloodstream infection without laboratory results. Because traditional blood culture testing is slow, clinicians often prescribe empiric therapy while awaiting results. This can lead to overuse of unnecessary antimicrobials.
Faster answers with a blood culture identification panel can allow clinicians to make faster therapy decisions. The first-generation BioFire® FilmArray® Blood Culture Identification (BCID) Panel combined with antimicrobial stewardship interventions decreased time to optimal therapy by 33.5 hours in the pediatric population.1
Fast answers don’t only help with faster therapy, they can support antimicrobial stewardship as well. The IDSA recommends the addition of rapid diagnostic testing and an active ASP to improve clinical outcomes.2 One study demonstrated that pairing the BioFire BCID Panel with antimicrobial stewardship provided the greatest benefit in terms of antimicrobial de-escaltion.3
The authors of a study about the benefits of adding the BioFire BCID Panel to an established antimicrobial stewardship program, stated: “Adding the BCID to our ASP intervention was clearly beneficial, as time to effective therapy and time to first antimicrobial de-escalation occurred more rapidly, and utilization of narrow-spectrum therapies significantly increased, with no harmful effects on patient care.”4